As of Friday close, AbbVie Inc.’s (NYSE:ABBV) stock was down -$0.79, moving down -0.51 percent to $153.50. The average number of shares traded per day over the past five days has been 6,487,460 shares. 3 times new highs have been achieved over the past 5 days, with a $0.67 gain in that time frame. In the last twenty days, the average volume was 7,871,555, while in the previous 50 days, it was 7,520,788.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, ABBV stock retreated -3.43%. Shares of the company fell to $139.93 on 04/29/22, the lowest level in the past month. A 52-week high of $175.91 was reached on 04/08/22 after having rallying from a 52-week low of $105.56. Since the beginning of this year, ABBV’s stock price has risen by 13.37% or $18.10, and marked a new high 32 times. However, the stock has declined by -12.74% since its 52-week high.
AbbVie Inc. (ABBV) last reported insider trading activity 4 days ago on May 10. SEVERINO MICHAEL, the Vice Chairman of the company, disposed of 100,000 shares for $152.28 on May 10. It resulted in a $15,227,966 divestment by the insider. SEVERINO MICHAEL sold 100,000 shares at an average price of $150.28 on May 09. The insider now owns 152,103 shares following the transaction. On May 06, Vice Chairman SEVERINO MICHAEL sold 100,000 shares at $150.81 apiece. The transaction was valued at $15,080,612.
Right now, AbbVie Inc. (ABBV) has a P/E ratio of about 23.80. The stock’s beta is 0.81. Besides these, the trailing price-to-sales (P/S) ratio of 4.80, the price-to-book (PB) ratio of 17.66, and the price-to-cash flow ratio of 21.38 may also be considered.
The latest dividend of $1.41 per share was paid out, remained unchanged from last year’s $1.41. On Friday October 29 2021, a $0.11 dividend increase was announced.
In the three months ended September 29, AbbVie Inc.’s quick ratio stood at 0.70, while its current ratio was 0.80, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 4.17, and the total debt-to-equity ratio was 4.98. On the profitability front, the trailing twelve-month gross margin is 69.20% percent. In the year ended September 29, operating margins totaled 29.50%. Based on annual data, ABBV earned $38.75 billion in gross profit and brought in $56.2 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 17.90%. Return on equity (ROE) for the past 12 months was 54.00%.
In AbbVie Inc.’s quarter-end financial report for September 29, it reported total debt of $63.52 billion against cash and short-term investments of $1.47 billion. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. ABBV’s revenue rose 3.9% to $14.89 billion during the quarter, while net income inched up to $13.54 billion. While analysts expected AbbVie Inc. to report $3.22 quarterly earnings, the actual figure was $3.33 per share, beating the consensus estimate by 3.40%. During the quarter, the company generated $6.77 billion in EBITDA. The liabilities of AbbVie Inc. were 126.9 billion at the end of its most recent quarter ended September 29, and its total debt was $80.74 billion. The value of shareholders’ equity is $1.77 billion.
This quick technical analysis looks at AbbVie Inc.’s (ABBV) price momentum. With a historical volatility rate of 13.10%, the RSI 9-day stood at 48.59% on 13 May.
With respect to its five-day moving average, the current AbbVie Inc. price is up by +0.44% percent or $0.67. At present, ABBV shares trade -5.43% below its 20-day simple moving average and +17.30% percent above its 100-day simple moving average. However, the stock is currently trading approximately +2.05% above its SMA50 and +29.13% above its SMA200.
Stochastic coefficient K was 67.41% and Stochastic coefficient D was 63.28%, while ATR was 4.48. Given the Stochastic reading of 68.67% for the 14-day period, the RSI (14) reading has been calculated as 47.19%. As of today, the MACD Oscillator reading stands at 1.14, while the 14-day reading stands at 0.83.
AbbVie Inc. downgraded its rating on AbbVie Inc. (NYSE: ABBV) to a Neutral in a note to investors on May 06, 2022. The analysts firm previously had an Outperform rating on the stock.